CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

French animal health firm Vetoquinol's Q3 sales rise on Essentials segment growth

By Reuters News


Overview

  • France animal health firm's Q3 sales rose 10.4% yr/yr, driven by Essentials segment growth

  • Essentials segment sales grew 13.9% in Q3, outpacing overall company growth

  • Q3 growth benefited from a favorable base effect and currency tailwinds


Outlook

  • Company did not provide specific guidance for future quarters or full-year 2026 in the press release


Result Drivers

  • ESSENTIALS SEGMENT - Essentials product sales grew faster than overall company sales, driving Q3 results

  • CURRENCY IMPACT - Favorable currency movements, mainly in the US and Americas, contributed €1 mln to Q3 sales

  • PRODUCT LINE SIMPLIFICATION - Simplification of complementary product lines reduced Q3 sales by €0.6 mln


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

EUR 140 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Vetoquinol SA is €86.00, about 7.8% above its October 27 closing price of €79.80

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago


Reuters Recommended Reads

  • Oct 28 - Higher prices lift Danone third-quarter sales

  • Oct 28 - France's Remy Cointreau H1 sales rise, helped by Cognac growth in Asia


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.